Oryzon Genomics wins U.S. patent for vafidemstat use in borderline personality disorder

  • Oryzon Genomics SA won a U.S. patent covering vafidemstat to treat non-aggressive symptoms of borderline personality disorder.
  • The patent expires in March 2043, including 1,095 days of patent term adjustment.
  • Canada issued a notice of allowance for a corresponding application covering the same use.
  • Vafidemstat remains in clinical development, with a Phase III trial in preparation for aggression in BPD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.